Many of us were expecting Q1 to produce secondary
Post# of 72447
(Total Views: 156)
Posted On: 12/27/2017 11:16:59 AM
Many of us were expecting Q1 to produce secondary endpoint analyses of B-OM study and the top line results for P trial. I would like to add that I now believe Q1 will produce a major announcement regarding the availability of K in a pill form ready for testing on healthy people (as I believe that is the first test for the oral form of a product) to determine if body handles it well and flushes it in a timely manner from the body.
A deal is still the catalyst for immediate, rapid price gain but the progress of K in an oral form is the long term rocket building momentum for the advancement of K and that is the product that will take IPIX from a great investment to a possibly once in a lifetime investment. The safety and efficacy shown so far certainly leads me to believe we have a damned fine chance of having Kevetrin become the giant killer Dr Menon had envisioned it to become.
Best Christmas present ever!!!
A deal is still the catalyst for immediate, rapid price gain but the progress of K in an oral form is the long term rocket building momentum for the advancement of K and that is the product that will take IPIX from a great investment to a possibly once in a lifetime investment. The safety and efficacy shown so far certainly leads me to believe we have a damned fine chance of having Kevetrin become the giant killer Dr Menon had envisioned it to become.
Best Christmas present ever!!!
(6)
(0)